Jun 2014

Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100Puffs

Japan

  • Meptin achieves rapid onset of action, targeting beta 2 adrenergic receptors and thereby causing smooth muscle relaxation and dilation of bronchial passages in the lungs. Meptin is widely used for asthma attacks and has a market share in Japan exceeding 50%. The new Meptin® Swinghaler® fits in the palm of the hand and enables fast inhalation by patients with asthma and chronic obstructive pulmonary disease (COPD).
  • In Japan, there are an estimated 1.05 million asthma patients and approximately 2,000 deaths per year related to asthma, many among the elderly. During mild asthma attacks, it is crucial that pediatric and elderly patients be able to simply, rapidly and reliably use an inhaler, therefore Otsuka Pharmaceutical and Otsuka Techno Corporation jointly developed a newly-designed dry-powder inhaler named Swinghaler.
  • With the launch of Meptin Swinghaler, Meptin is now available in 12 dosage forms suited for the age and disease status of individual asthma and COPD patients. The product is marketed in twelve countries and regions.

Otsuka has announced that Meptin Swinghaler, an improved inhaler containing 100 puffs of a 10-microgram dose of Meptin dry powder, will be launched in Japan on July 2. Meptin Swinghaler, a successor to the Meptin Clickhaler introduced in 2005, offers improved features such as greater compactness for use anywhere, moisture-proof, one-click closure and a dose counter indicating the number of remaining doses.

Information in this news release was current as of the original release date.

 

Otsuka Pharmaceutical Co., Ltd. (OPC) is a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health. 

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. 

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company that commercializes Otsuka medicines in Canada. OCPI aims to improve the quality of life and health of patients through its commitments to neuroscience, cardiovascular health, oncology and nephrology. OCPI was established in 2010, with headquarters in Saint-Laurent, Quebec.

 

OCPI is part of Otsuka Pharmaceutical Co., Ltd., a wholly owned subsidiary of Otsuka Holdings Co., Ltd., based in Tokyo, Japan. The Otsuka group of companies employed 45,000 people worldwide and had consolidated sales of approximately CAD 14.5 billion (USD 11 billion) in 2016.

About Us
Contact Us

1 888 997-9017
514 332-3001

Location
2250 Alfred-Nobel Boulevard,
St-Laurent, Quebec,
Suite 301
H4S 2C9


Legal